Overview

A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection

Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
The investigators propose to evaluate efficacy and safety of gemcitabine in the adjuvant treatment of cholangiocarcinoma after potentially curative treatment with surgical resection.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Collaborator:
Dong-A Pharmaceutical Co., Ltd.
Treatments:
Gemcitabine